• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of gutGutView this articleSubmit a manuscriptReceive email alertsContact usBMJ
Gut. Jun 1998; 42(6): 788–791.
PMCID: PMC1727156

Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role


Background—Perinuclear antineutrophil cytoplasmic autoantibodies (pANCA) are a well recognised marker for ulcerative colitis. Antibodies to oligomannosidic epitopes of the yeast Saccharomyces cerevisiae (ASCA) are a new marker associated with Crohn's disease.
Aims—To assess the value of detecting pANCA and/or ASCA for the diagnosis of ulcerative colitis and Crohn's disease.
Methods—Serum samples were obtained from 100 patients with Crohn's disease, 101 patients with ulcerative colitis, 27 patients with other miscellaneous diarrhoeal illnesses, and 163 healthy controls. Determination of pANCA and ASCA was performed using the standardised indirect immunofluorescence technique and an ELISA, respectively.
Results—The combination of a positive pANCA test and a negative ASCA test yielded a sensitivity, specificity, and positive predictive value of 57%, 97%, and 92.5% respectively for ulcerative colitis. The combination of a positive ASCA test and a negative pANCA test yielded a sensitivity, specificity, and positive predictive value of 49%, 97%, and 96% respectively for Crohn's disease. Among patients with miscellaneous non-inflammatory bowel disorders, three were ASCA positive and two were pANCA positive. One control was ASCA positive. The presence of ASCA in patients with Crohn's disease was associated with small bowel involvement.
Conclusion—ASCA and pANCA are strongly associated with Crohn's disease and ulcerative colitis, respectively. Combination of both tests could help the diagnosis of inflammatory bowel disease.

Keywords: Crohn's disease; ulcerative colitis; antineutrophil cytoplasmic autoantibodies; anti-Saccharomyces cerevisiae mannan antibodies

Full Text

The Full Text of this article is available as a PDF (110K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Gower-Rousseau C, Salomez JL, Dupas JL, Marti R, Nuttens MC, Votte A, Lemahieu M, Lemaire B, Colombel JF, Cortot A. Incidence of inflammatory bowel disease in northern France (1988-1990). Gut. 1994 Oct;35(10):1433–1438. [PMC free article] [PubMed]
  • Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990 Aug;86(2):202–210. [PubMed]
  • Rump JA, Schölmerich J, Gross V, Roth M, Helfesrieder R, Rautmann A, Lüdemann J, Gross WL, Peter HH. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology. 1990 Nov;181(4-5):406–413. [PubMed]
  • Duerr RH, Targan SR, Landers CJ, Sutherland LR, Shanahan F. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology. 1991 Jun;100(6):1590–1596. [PubMed]
  • Colombel JF, Reumaux D, Duthilleul P, Noël LH, Gower-Rousseau C, Paris JC, Cortot A. Antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseases. Gastroenterol Clin Biol. 1992;16(8-9):656–660. [PubMed]
  • Cambridge G, Rampton DS, Stevens TR, McCarthy DA, Kamm M, Leaker B. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1992 May;33(5):668–674. [PMC free article] [PubMed]
  • Oudkerk Pool M, Ellerbroek PM, Ridwan BU, Goldschmeding R, von Blomberg BM, Peña AS, Dolman KM, Bril H, Dekker W, Nauta JJ, et al. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut. 1993 Jan;34(1):46–50. [PMC free article] [PubMed]
  • Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR, Parratt D. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ. 1988 Oct 29;297(6656):1105–1106. [PMC free article] [PubMed]
  • Barnes RM, Allan S, Taylor-Robinson CH, Finn R, Johnson PM. Serum antibodies reactive with Saccharomyces cerevisiae in inflammatory bowel disease: is IgA antibody a marker for Crohn's disease? Int Arch Allergy Appl Immunol. 1990;92(1):9–15. [PubMed]
  • Giaffer MH, Clark A, Holdsworth CD. Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance. Gut. 1992 Aug;33(8):1071–1075. [PMC free article] [PubMed]
  • Sendid B, Colombel JF, Jacquinot PM, Faille C, Fruit J, Cortot A, Lucidarme D, Camus D, Poulain D. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol. 1996 Mar;3(2):219–226. [PMC free article] [PubMed]
  • Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology. 1979 Oct;77(4 Pt 2):843–846. [PubMed]
  • TRUELOVE SC, WITTS LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955 Oct 29;2(4947):1041–1048. [PMC free article] [PubMed]
  • Wiik A. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. APMIS Suppl. 1989;6:12–13. [PubMed]
  • Campbell G. Advances in statistical methodology for the evaluation of diagnostic and laboratory tests. Stat Med. 13(5-7):499–508. [PubMed]
  • Reumaux D, Colombel JF, Delecourt L, Noël LH, Cortot A, Duthilleul P. Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in patients with ulcerative colitis (UC): influence of disease activity and familial study. Adv Exp Med Biol. 1993;336:515–518. [PubMed]
  • Reumaux D, Colombel JF, Duclos B, Chaussade S, Belaïche J, Jacquot S, Dupas JL, Molis C, Duthilleul P. Antineutrophil cytoplasmic auto-antibodies in sera from patients with ulcerative colitis after proctocolectomy with ileo-anal anastomosis. Adv Exp Med Biol. 1993;336:523–525. [PubMed]
  • Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H, Rotter JI, Vidrich A, Targan SR. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology. 1996 Jun;110(6):1810–1819. [PubMed]
  • Jamar-Leclerc N, Reumaux D, Duthilleul P, Colombel JF. Do pANCA define a clinical subgroup in patients with Crohn's disease? Gastroenterology. 1997 Jan;112(1):316–317. [PubMed]
  • Jamar-Leclerc N, Reumaux D, Duthilleul P, Colombel JF. Do pANCA define a clinical subgroup in patients with Crohn's disease? Gastroenterology. 1997 Jan;112(1):316–317. [PubMed]
  • Polito JM, 2nd, Childs B, Mellits ED, Tokayer AZ, Harris ML, Bayless TM. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology. 1996 Sep;111(3):580–586. [PubMed]
  • Colombel JF, Grandbastien B, Gower-Rousseau C, Plegat S, Evrard JP, Dupas JL, Gendre JP, Modigliani R, Bélaïche J, Hostein J, et al. Clinical characteristics of Crohn's disease in 72 families. Gastroenterology. 1996 Sep;111(3):604–607. [PubMed]

Figures and Tables

Figure 1
ASCA and ANCA results in the different study groups.

Articles from Gut are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...